Loading...

Idera Pharmaceuticals

DB:HXXB
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HXXB
DB
$67M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Idera Pharmaceuticals has significant price volatility in the past 3 months.
HXXB Share Price and Events
7 Day Returns
-16.2%
DB:HXXB
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-81.8%
DB:HXXB
-9.2%
DE Biotechs
-6.7%
DE Market
HXXB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Idera Pharmaceuticals (HXXB) -16.2% -19.8% -20.2% -81.8% -84% -89.2%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • HXXB underperformed the Biotechs industry which returned -9.2% over the past year.
  • HXXB underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
HXXB
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Idera Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Idera Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €2.052.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Idera Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Idera Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HXXB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.25
NasdaqCM:IDRA Share Price ** NasdaqCM (2019-04-18) in USD $2.39
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Idera Pharmaceuticals.

DB:HXXB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:IDRA Share Price ÷ EPS (both in USD)

= 2.39 ÷ -2.25

-1.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idera Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Idera Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Idera Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:HXXB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
40.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Idera Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Idera Pharmaceuticals's assets?
Raw Data
DB:HXXB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.35
NasdaqCM:IDRA Share Price * NasdaqCM (2019-04-18) in USD $2.39
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:HXXB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:IDRA Share Price ÷ Book Value per Share (both in USD)

= 2.39 ÷ 2.35

1.02x

* Primary Listing of Idera Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idera Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Idera Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Idera Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Idera Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Idera Pharmaceuticals expected to grow at an attractive rate?
  • Idera Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Idera Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Idera Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HXXB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HXXB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 40.2%
DB:HXXB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 59.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HXXB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HXXB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 230 74 2
2022-12-31 135 13 2
2021-12-31 36 -81 -60 3
2020-12-31 3 -92 -70 4
2019-12-31 0 -75 -61 4
DB:HXXB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -52 -60
2018-09-30 1 -52 -63
2018-06-30 1 -52 -66
2018-03-31 1 -52 -71
2017-12-31 1 -55 -66
2017-09-30 16 -39 -50
2017-06-30 16 -38 -49
2017-03-31 16 -33 -41
2016-12-31 16 -28 -38
2016-09-30 1 -42 -51
2016-06-30 1 -43 -50
2016-03-31 1 -43 -49

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Idera Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Idera Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HXXB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Idera Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HXXB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.92 1.04 0.79 2.00
2022-12-31 0.12 0.31 -0.08 2.00
2021-12-31 -1.40 -0.73 -2.09 4.00
2020-12-31 -1.83 -1.33 -2.58 4.00
2019-12-31 -1.89 -1.37 -2.49 4.00
DB:HXXB Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.25
2018-09-30 -2.46
2018-06-30 -2.81
2018-03-31 -3.34
2017-12-31 -3.35
2017-09-30 -2.70
2017-06-30 -2.75
2017-03-31 -2.42
2016-12-31 -2.41
2016-09-30 -3.39
2016-06-30 -3.31
2016-03-31 -3.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Idera Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Idera Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Idera Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Idera Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Idera Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Idera Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Idera Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Idera Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Idera Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Idera Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HXXB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.66 -59.88 15.42 15.81
2018-09-30 0.74 -62.66 16.68 19.47
2018-06-30 0.76 -65.58 16.71 24.41
2018-03-31 0.78 -71.02 19.61 24.82
2017-12-31 0.90 -65.98 15.59 25.66
2017-09-30 16.01 -50.24 15.42 26.48
2017-06-30 16.17 -48.61 15.41 24.89
2017-03-31 16.28 -40.62 15.30 24.97
2016-12-31 16.20 -38.39 15.13 24.10
2016-09-30 1.11 -51.20 15.31 22.48
2016-06-30 0.81 -49.66 15.43 21.06
2016-03-31 0.51 -48.90 15.48 21.60
2015-12-31 0.25 -48.56 15.40 20.46
2015-09-30 0.06 -48.58 15.37 19.45
2015-06-30 0.07 -46.79 14.22 19.65
2015-03-31 0.10 -42.50 13.13 17.12
2014-12-31 0.07 -39.16 11.33 16.23
2014-09-30 0.08 -33.52 10.08 14.18
2014-06-30 0.05 -28.96 9.39 11.28
2014-03-31 0.04 -26.15 8.26 8.95
2013-12-31 0.05 -21.09 7.74 6.98
2013-09-30 0.05 -21.25 6.57 6.60
2013-06-30 0.05 -21.06 5.87 7.53
2013-03-31 0.05 -19.49 6.12 8.83
2012-12-31 0.05 -22.45 6.28 13.17
2012-09-30 0.05 -25.63 6.55 12.07
2012-06-30 0.05 -26.29 7.02 12.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Idera Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Idera Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Idera Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Idera Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Idera Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Idera Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Idera Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Idera Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Idera Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Idera Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Idera Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Idera Pharmaceuticals Company Filings, last reported 3 months ago.

DB:HXXB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 63.99 0.00 71.43
2018-09-30 74.87 0.00 82.46
2018-06-30 85.07 0.00 94.05
2018-03-31 98.88 0.13 107.46
2017-12-31 107.70 0.21 112.63
2017-09-30 62.08 0.29 65.34
2017-06-30 74.87 0.36 77.24
2017-03-31 90.19 0.43 91.26
2016-12-31 103.35 0.50 109.01
2016-09-30 49.87 0.57 52.01
2016-06-30 61.05 0.64 61.46
2016-03-31 72.68 0.70 62.39
2015-12-31 83.58 0.76 60.16
2015-09-30 92.66 0.82 66.02
2015-06-30 102.51 0.88 75.74
2015-03-31 113.27 0.88 113.46
2014-12-31 43.40 0.87 41.23
2014-09-30 52.82 0.86 58.28
2014-06-30 60.26 0.00 63.73
2014-03-31 66.88 0.00 70.64
2013-12-31 32.45 0.00 29.40
2013-09-30 37.11 0.00 38.75
2013-06-30 13.93 0.00 16.30
2013-03-31 2.71 0.00 6.15
2012-12-31 6.63 0.00 10.10
2012-09-30 3.66 0.00 8.35
2012-06-30 7.98 0.00 13.23
  • Idera Pharmaceuticals has no debt.
  • Idera Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Idera Pharmaceuticals has sufficient cash runway for 1.4 years based on current free cash flow.
  • Idera Pharmaceuticals has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 10.7% each year.
X
Financial health checks
We assess Idera Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Idera Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Idera Pharmaceuticals dividends.
If you bought €2,000 of Idera Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Idera Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Idera Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HXXB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HXXB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Idera Pharmaceuticals has not reported any payouts.
  • Unable to verify if Idera Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Idera Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Idera Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Idera Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Idera Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Idera Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Idera Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vinnie, Vin Milano
COMPENSATION $1,781,944
AGE 54
TENURE AS CEO 4.3 years
CEO Bio

Mr. Vincent J. Milano, also known as Vinnie and Vin, has been the Chief Executive Officer and President at Idera Pharmaceuticals, Inc. since December 1, 2014. Mr. Milano served as the Chief Executive Officer and President of ViroPharma Inc. from March 31, 2008 to January 24, 2014. He served as the Chief Operating Officer of ViroPharma Inc., from January 2006 to March 2008, Vice President from November 1997 to March 2008, Chief Financial Officer from November 1997 to October 2008, Treasurer from July 1996 to 2006 and Principal Accounting Officer until April 2008. Mr. Milano served as an Executive Director of Finance and Administration at ViroPharma Inc., from April 1996 to February 1997 and Vice President of Finance and Administration from February 1997 to November 1997. From 1985 to 1996, he served with KPMG LLP, independent certified public accountants, where he served as Senior Manager from 1991 to 1996. He joined ViroPharma in April 1996 has led over $400 million of financings, including its initial public offering, follow-on offerings, private placements and convertible debt financings. He served as the Chairman at ViroPharma from December 2008 to January 24, 2014. He has been a Director at Spark Therapeutics, Inc. since June 2014. Mr. Milano has been a Director of BravoSolution US, Inc. since August 5, 2003 and Pennsylvania Bio since April 20, 2011. He has been Independent Director of Vanda Pharmaceuticals, Inc. since April 21, 2010.He has been Director of VenatoRx and Idera Pharmaceuticals, Inc since December 2014. He served as Director of ViroPharma Inc. from February 2008 to January 24, 2014. He has been a Director and a Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He serves as a Director at The Pennsylvania Biotechnology Association. He is a Certified Public Accountant and received his B.S. in Commerce/Accounting from Rider College

CEO Compensation
  • Vinnie, Vin's compensation has increased whilst company is loss making.
  • Vinnie, Vin's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Idera Pharmaceuticals management team in years:

2.7
Average Tenure
54.5
Average Age
  • The tenure for the Idera Pharmaceuticals management team is about average.
Management Team

Vinnie, Vin Milano

TITLE
President
COMPENSATION
$2M
AGE
54
TENURE
4.3 yrs

John Kirby

TITLE
VP of Finance
COMPENSATION
$554K
AGE
46
TENURE
0.5 yrs

Jonathan Yingling

TITLE
Senior VP of Early Development & Chief Scientific Officer
COMPENSATION
$976K
AGE
49
TENURE
1.3 yrs

Robert Fletcher

TITLE
Senior Vice President of Business Development & Strategic Planning
COMPENSATION
$977K
AGE
55
TENURE
4.3 yrs

Joanna Horobin

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$994K
AGE
63
TENURE
3.4 yrs

Lou Arcudi

TITLE
COMPENSATION
$986K
AGE
57
TENURE
0.5 yrs

Robert Doody

TITLE
Senior Vice President of IR & Corporate Communications
TENURE
4.3 yrs

Bryant Lim

TITLE
Senior VP
AGE
46
TENURE
0.6 yrs

Jill Conwell

TITLE
Senior Vice President of Human Resources
TENURE
4.2 yrs

Sudhir Agrawal

TITLE
Scientific Advisor
COMPENSATION
$5M
AGE
64
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Idera Pharmaceuticals board of directors in years:

4.3
Average Tenure
60
Average Age
  • The tenure for the Idera Pharmaceuticals board of directors is about average.
Board of Directors

Jim Geraghty

TITLE
Chairman
COMPENSATION
$153K
AGE
63
TENURE
5.8 yrs

Vinnie, Vin Milano

TITLE
President
COMPENSATION
$2M
AGE
54
TENURE
4.3 yrs

Max Gowen

TITLE
Director
COMPENSATION
$101K
AGE
60
TENURE
3.3 yrs

Carol Schafer

TITLE
Director
COMPENSATION
$52K
AGE
55
TENURE
0.3 yrs

Mark Goldberg

TITLE
Director
COMPENSATION
$100K
AGE
64
TENURE
5.3 yrs

Kelvin Neu

TITLE
Director
COMPENSATION
$105K
AGE
45
TENURE
5.1 yrs

Howard Pien

TITLE
Director
COMPENSATION
$142K
AGE
60
TENURE
0.6 yrs

Mike Dougherty

TITLE
Director
AGE
60

Cristina Csimma

TITLE
Director
AGE
59
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Dec 18 Buy Carol Schafer Individual 19. Dec 18 19. Dec 18 5,000 €2.92 €14,590
26. Dec 18 Buy Vincent Milano Individual 24. Dec 18 24. Dec 18 15,000 €2.57 €38,503
26. Dec 18 Buy Bryant Lim Individual 21. Dec 18 21. Dec 18 4,000 €2.67 €10,690
20. Dec 18 Buy Joanna Horobin Individual 20. Dec 18 20. Dec 18 300 €3.02 €907
20. Dec 18 Buy Mark Goldberg Individual 19. Dec 18 19. Dec 18 10,000 €2.79 €27,916
17. Aug 18 Sell Pillar Invest Corporation Company 07. Aug 18 07. Aug 18 -75,000 €4.85 €-363,858
17. Aug 18 Sell Pillar Invest Corporation Company 07. Aug 18 09. Aug 18 -225,000 €5.49 €-1,139,007
08. Aug 18 Buy Vincent Milano Individual 07. Aug 18 07. Aug 18 10,000 €4.75 €47,540
08. Aug 18 Buy James Geraghty Individual 07. Aug 18 07. Aug 18 10,000 €4.81 €48,144
24. Jul 18 Sell Pillar Invest Corporation Company 18. Jul 18 20. Jul 18 -346,696 €6.02 €-2,034,948
19. Jul 18 Sell Pillar Invest Corporation Company 13. Jul 18 17. Jul 18 -232,597 €7.21 €-1,599,973
X
Management checks
We assess Idera Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Idera Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.

Details
Name: Idera Pharmaceuticals, Inc.
HXXB
Exchange: DB
Founded: 1989
$59,707,147
27,620,102
Website: http://www.iderapharma.com
Address: Idera Pharmaceuticals, Inc.
505 Eagleview Boulevard,
Suite 212,
Exton,
Pennsylvania, 19341,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM IDRA Common Stock Nasdaq Capital Market US USD 25. Jan 1996
DB HXXB Common Stock Deutsche Boerse AG DE EUR 25. Jan 1996
Number of employees
Current staff
Staff numbers
36
Idera Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:23
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.